Application of direct renin inhibition to chronic kidney disease

Cardiovascular Drugs and Therapy

Volumn 24, Issue 2, 2010, Pages 139-149

  Mende, Christian W ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Aliskiren; Angiotensin; Kidney disease; Renin

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; PRORENIN; PRORENIN RECEPTOR; RAMIPRIL; RECEPTOR PROTEIN; RENIN; RENIN INHIBITOR; RENIN RECEPTOR; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIARRHEA; DISEASE COURSE; DISEASE MARKER; DIZZINESS; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME INHIBITION; GLOMERULOSCLEROSIS; HEART DISEASE; HORMONE ACTION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; LEG EDEMA; MONOTHERAPY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; THERAPY EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; RENAL INSUFFICIENCY, CHRONIC;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RENIN;

EID: 77955415650     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-010-6232-1     Document Type: Review

References (86)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1-266.
2. J Coresh E Selvin LA Stevens, et al. 2007 Prevalence of chronic kidney disease in the United States JAMA 298 2038 2047 10.1001/jama.298.17.2038 1:CAS:528:DC%2BD2sXht1yjsLnM 17986697 (Pubitemid 350074801)
3. MMWR 2007 Prevalence of chronic kidney disease and associated risk factors-United States, 1999-2004 Morb Mortal Wkly Rep 56 161 165
4. United States Renal Data System.Available at: www.usrds.org.
5. RN Foley AJ Collins 2007 End-stage renal disease in the United States: an update from the United States Renal Data System J Am Soc Nephrol 18 2644 2648 10.1681/ASN.2007020220 17656472 (Pubitemid 47531190)
6. F Laliberte BK Bookhart F Vekeman, et al. 2009 Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective J Manag Care Pharm 15 312 322 19422271
7. AS Go GM Chertow D Fan CE McCulloch CY Hsu 2004 Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 1296 1305 10.1056/NEJMoa041031 1:CAS:528:DC%2BD2cXnvFSgtr8%3D 15385656 (Pubitemid 39268908)
8. EJ Lewis LG Hunsicker RP Bain RD Rohde 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1456 1462 10.1056/NEJM199311113292004 1:STN:280:DyaK2c%2FhvFKitQ%3D%3D 8413456 (Pubitemid 23335891)
9. EJ Lewis LG Hunsicker WR Clarke, et al. 2001 Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 851 860 10.1056/NEJMoa011303 1:CAS:528:DC%2BD3MXntlelsLg%3D 11565517
10. BM Brenner ME Cooper D de Zeeuw, et al. 2001 Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861 869 10.1056/NEJMoa011161 1:CAS:528:DC%2BD3MXntlelsLk%3D 11565518
11. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49:S12-154.
12. SA Atlas 2007 The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition J Manag Care Pharm 13 9 20 17970613
13. YC Li J Kong M Wei, et al. 2002 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system J Clin Invest 110 229 238 1:CAS:528:DC%2BD38XlsVGlsbg%3D 12122115
14. M Mazzali J Hughes YG Kim, et al. 2001 Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism Hypertension 38 1101 1106 10.1161/hy1101.092839 1:CAS:528:DC%2BD3MXovVOrsbg%3D 11711505
15. LJ Ellmers NJ Scott S Medicherla, et al. 2008 Transforming growth factor-beta blockade down-regulates the renin-angiotensin system and modifies cardiac remodeling after myocardial infarction Endocrinology 149 5828 5834 10.1210/en.2008-0165 1:CAS:528:DC%2BD1cXhtlWnsrfM 18653707
16. V Todorov M Muller F Schweda A Kurtz 2002 Tumor necrosis factor-alpha inhibits renin gene expression Am J Physiol Regul Integr Comp Physiol 283 R1046 1051 12376397
17. A Ribeiro-Oliveira Jr AI Nogueira RM Pereira, et al. 2008 The renin-angiotensin system and diabetes: an update Vasc Health Risk Manag 4 787 803 1:CAS:528:DC%2BD1cXht1Shur%2FK 19065996
18. CM Ferrario 2006 Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation Hypertension 47 515 521 10.1161/01.HYP.0000196268.08909.fb 1:CAS:528:DC%2BD28XhsFKlurc%3D 16365192 (Pubitemid 43843868)
19. M Ye J Wysocki J William, et al. 2006 Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes J Am Soc Nephrol 17 3067 3075 10.1681/ASN.2006050423 1:CAS:528:DC%2BD28Xht1yjtbrP 17021266 (Pubitemid 44707767)
20. DW Wong GY Oudit H Reich, et al. 2007 Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury Am J Pathol 171 438 451 10.2353/ajpath.2007.060977 1:CAS:528:DC%2BD2sXpsFaitbY%3D 17600118 (Pubitemid 47344677)
21. M Paul A Poyan Mehr R Kreutz 2006 Physiology of local renin-angiotensin systems Physiol Rev 86 747 803 10.1152/physrev.00036.2005 1:CAS:528: DC%2BD28XnsFGgtLk%3D 16816138 (Pubitemid 44033382)
22. H Kobori M Nangaku LG Navar A Nishiyama 2007 The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease Pharmacol Rev 59 251 287 10.1124/pr.59.3.3 1:CAS:528:DC%2BD2sXht1ahsr3E 17878513 (Pubitemid 47481436)
23. DH Endemann EL Schiffrin 2004 Endothelial dysfunction J Am Soc Nephrol 15 1983 1992 10.1097/01.ASN.0000132474.50966.DA 1:CAS:528:DC%2BD2cXlvVKmurY%3D 15284284 (Pubitemid 39031337)
24. C Ruster G Wolf 2006 Renin-angiotensin-aldosterone system and progression of renal disease J Am Soc Nephrol 17 2985 2991 10.1681/ASN.2006040356 17035613 (Pubitemid 44707758)
25. M Epstein 2001 Aldosterone as a determinant of cardiovascular and renal dysfunction J R Soc Med 94 378 383 1:CAS:528:DC%2BD3MXntVKitrY%3D 11461980
26. NJ Brown 2008 Aldosterone and vascular inflammation Hypertension 51 161 167 10.1161/HYPERTENSIONAHA.107.095489 1:CAS:528:DC%2BD1cXmt1OhsQ%3D%3D 18172061 (Pubitemid 351159920)
27. CA Farquharson AD Struthers 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure Circulation 101 594 597 1:CAS:528:DC%2BD3cXhtlGntL4%3D 10673249
28. G Nguyen F Delarue C Burckle, et al. 2002 Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin J Clin Invest 109 1417 1427 1:CAS:528:DC%2BD38XktlWlu78%3D 12045255
29. Danser AJ. The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor? Hypertens Res 2009:[Epub ahead of print].
30. NK Hollenberg 2010 Direct renin inhibition and the kidney Nat Rev Nephrol 6 49 55 10.1038/nrneph.2009.201 1:CAS:528:DC%2BD1MXhsFyiurfF 19935744
31. Y Huang S Wongamorntham J Kasting, et al. 2006 Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms Kidney Int 69 105 113 10.1038/sj.ki.5000011 1:CAS:528:DC%2BD28Xpt1Wqtw%3D%3D 16374430 (Pubitemid 43117745)
32. Reudelhuber TL. Prorenin, Renin, and Their Receptor. Moving Targets. Hypertension 2010.
33. T Yamamoto T Nakagawa H Suzuki, et al. 2007 Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease J Am Soc Nephrol 18 1558 1565 10.1681/ASN.2006060554 1:CAS:528:DC%2BD2sXls1Gksr4%3D 17409316 (Pubitemid 46717523)
34. NK Hollenberg DA Price ND Fisher, et al. 2003 Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus Kidney Int 63 172 178 10.1046/j.1523-1755.2003.00701.x 1:CAS:528:DC%2BD3sXmtV2htg%3D%3D 12472780 (Pubitemid 35463918)
35. DA Price LE Porter M Gordon, et al. 1999 The paradox of the low-renin state in diabetic nephropathy J Am Soc Nephrol 10 2382 2391 1:CAS:528: DyaK1MXnsVegsLk%3D 10541298
36. S Mezzano A Droguett ME Burgos, et al. 2003 Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy Kidney Int Suppl 86 S64 70 10.1046/j.1523-1755.64.s86.12.x 1:CAS:528: DC%2BD3sXot1Wis7w%3D 12969130
37. S Anderson HG Rennke BM Brenner 1986 Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat J Clin Invest 77 1993 2000 10.1172/JCI112528 1:CAS:528:DyaL28XktFyit7g%3D 3011863
38. G Maschio D Alberti G Janin, et al. 1996 Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 939 945 10.1056/NEJM199604113341502 1:CAS:528:DyaK28XislKmsbg%3D 8596594 (Pubitemid 26114159)
39. MR Weir JC Fink 2005 Salt intake and progression of chronic kidney disease: an overlooked modifiable exposure? A commentary Am J Kidney Dis 45 176 188 10.1053/j.ajkd.2004.08.041 15696458 (Pubitemid 40038059)
40. DP Ng BC Tai D Koh KW Tan KS Chia 2005 Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14, 727 subjects Diabetologia 48 1008 1016 10.1007/s00125-005-1726-2 1:CAS:528:DC%2BD2MXktFyhtr8%3D 15830182 (Pubitemid 40767996)
41. HH Parving D de Zeeuw ME Cooper, et al. 2008 ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy J Am Soc Nephrol 19 771 779 10.1681/ASN.2007050582 1:CAS:528:DC%2BD1cXkvFOhtrw%3D 18199798
42. P Ruggenenti P Bettinaglio F Pinares G Remuzzi 2008 Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies Clin J Am Soc Nephrol 3 1511 1525 10.2215/CJN.04140907 18550651
43. G Giacchetti LA Sechi S Rilli RM Carey 2005 The renin-angiotensin- aldosterone system, glucose metabolism and diabetes Trends Endocrinol Metab 16 120 126 10.1016/j.tem.2005.02.003 1:CAS:528:DC%2BD2MXivV2gs7o%3D 15808810 (Pubitemid 40432462)
44. E Roig F Perez-Villa M Morales, et al. 2000 Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure Eur Heart J 21 53 57 10.1053/euhj.1999.1740 1:CAS:528:DC%2BD3cXpt1ygtQ%3D%3D 10610744 (Pubitemid 30042669)
45. XR Huang WY Chen LD Truong HY Lan 2003 Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease J Am Soc Nephrol 14 1738 1747 10.1097/01.ASN.0000071512.93927.4E 1:CAS:528:DC%2BD3sXksV2ju78%3D 12819233 (Pubitemid 36750469)
46. M Azizi J Menard 2004 Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists Circulation 109 2492 2499 10.1161/01.CIR.0000131449.94713.AD 15173039 (Pubitemid 38720545)
47. M Burnier HR Brunner 2000 Angiotensin II receptor antagonists Lancet 355 637 645 10.1016/S0140-6736(99)10365-9 1:CAS:528:DC%2BD3cXhvVGjsr4%3D 10696996
48. TH Jafar PC Stark CH Schmid, et al. 2003 Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis Ann Intern Med 139 244 252 1:CAS:528:DC%2BD3sXnt12kurs%3D 12965979
49. MA Pohl S Blumenthal DJ Cordonnier, et al. 2005 Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations J Am Soc Nephrol 16 3027 3037 10.1681/ASN.2004110919 1:CAS:528:DC%2BD2MXhtFegtLnE 16120823 (Pubitemid 44743500)
50. CE Mogensen S Neldam I Tikkanen, et al. 2000 Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 1440 1444 10.1136/bmj.321.7274. 1440 1:CAS:528:DC%2BD3MXjsFCkuw%3D%3D 11110735
51. JF Mann RE Schmieder M McQueen, et al. 2008 Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 547 553 10.1016/S0140-6736(08)61236-2 1:CAS:528:DC%2BD1cXpvFKgsLs%3D 18707986
52. D de Zeeuw G Remuzzi HH Parving, et al. 2004 Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 65 2309 2320 10.1111/j.1523-1755.2004.00653.x 15149345 (Pubitemid 38670018)
53. PA Sarafidis GL Bakris 2008 Renin-angiotensin blockade and kidney disease Lancet 372 511 512 10.1016/S0140-6736(08)61212-X 18707969
54. LF Fried W Duckworth JH Zhang, et al. 2009 Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D) Clin J Am Soc Nephrol 4 361 368 10.2215/CJN.03350708 1:CAS:528:DC%2BD1MXjslagur8%3D 19118120
55. A Maione A Nicolucci JC Craig, et al. 2007 Protocol of the Long-term Impact of RAS Inhibition on Cardiorenal Outcomes (LIRICO) randomized trial J Nephrol 20 646 655 1:CAS:528:DC%2BD1cXlvVGru78%3D 18046666
56. NK Hollenberg HH Parving G Viberti, et al. 2007 Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus J Hypertens 25 1921 1926 10.1097/HJH.0b013e328277596e 1:CAS:528:DC%2BD2sXpslalu74%3D 17762658 (Pubitemid 47356634)
57. K Rossing KJ Schjoedt BR Jensen F Boomsma HH Parving 2005 Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 68 1190 1198 10.1111/j.1523-1755.2005. 00511.x 1:CAS:528:DC%2BD2MXhtVCjt73E 16105050 (Pubitemid 43246436)
58. E Burgess N Muirhead P Rene de Cotret, et al. 2009 Supramaximal dose of candesartan in proteinuric renal disease J Am Soc Nephrol 20 893 900 10.1681/ASN.2008040416 1:CAS:528:DC%2BD1MXltFyjsro%3D 19211712
59. KJ Schjoedt S Andersen P Rossing L Tarnow HH Parving 2004 Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate Diabetologia 47 1936 1939 10.1007/s00125-004-1542-0 1:CAS:528:DC%2BD2cXhtVOqs7vJ 15551047 (Pubitemid 40110201)
60. U Wenzel 2008 Aldosterone and progression of renal disease Curr Opin Nephrol Hypertens 17 44 50 1:CAS:528:DC%2BD1cXhtFKiu78%3D 18090669
61. SD Navaneethan SU Nigwekar AR Sehgal GF Strippoli 2009 Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 542 551 10.2215/CJN.04750908 1:CAS:528:DC%2BD1MXktFKis78%3D 19261819
62. S Bianchi R Bigazzi VM Campese 2006 Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease Kidney Int 70 2116 2123 1:CAS:528:DC%2BD28Xht1Kju7bL 17035949
63. J Nussberger G Wuerzner C Jensen HR Brunner 2002 Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril Hypertension 39 E1 8 10.1161/hy0102.102293 1:CAS:528:DC%2BD38XpvVyktA%3D%3D 11799102
64. W Drummond MA Munger 2007 Rafique Essop M, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy J Clin Hypertens (Greenwich) 9 742 750 10.1111/j.1524-6175.2007.06614.x 1:CAS:528:DC%2BD2sXht12rt7%2FK
65. A Villamil SG Chrysant D Calhoun, et al. 2007 Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide J Hypertens 25 217 226 10.1097/HJH.0b013e3280103a6b 1:CAS:528:DC%2BD28Xht1OhtrnM 17143194 (Pubitemid 44885684)
66. Y Uresin AA Taylor C Kilo, et al. 2007 Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension J Renin Angiotensin Aldosterone Syst 8 190 198 10.3317/jraas.2007.028 1:CAS:528:DC%2BD1cXhs1yqsLY%3D 18205098 (Pubitemid 351166266)
67. S Oparil SA Yarows S Patel, et al. 2007 Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial Lancet 370 221 229 10.1016/S0140-6736(07)61124-6 1:CAS:528:DC%2BD2sXnvF2gsrc%3D 17658393 (Pubitemid 47069535)
68. M Azizi J Menard A Bissery, et al. 2004 Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption J Am Soc Nephrol 15 3126 3133 10.1097/01.ASN.0000146686.35541.29 15579516 (Pubitemid 39578845)
69. M Azizi J Menard A Bissery TT Guyene A Bura-Riviere 2007 Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals Clin J Am Soc Nephrol 2 947 955 10.2215/CJN.00360107 1:CAS:528:DC%2BD2sXhsVGqt73K 17702736
70. F Persson P Rossing H Reinhard, et al. 2009 Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria Diab Care 32 1873 1879 10.2337/dc09-0168 1:CAS:528:DC%2BD1MXhtlehs7nL
71. ND Fisher AH Jan Danser J Nussberger WP Dole NK Hollenberg 2008 Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans Circulation 117 3199 3205 10.1161/CIRCULATIONAHA.108.767202 1:CAS:528: DC%2BD1cXnt1ehs70%3D 18559696
72. SA Yarows 2010 Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases Expert Rev Cardiovasc Ther 8 19 33 10.1586/erc.09.143 1:CAS:528:DC%2BD1MXhsFKgu7jN 20030022
73. JJ McMurray B Pitt R Latini, et al. 2008 Effect of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure Circ Heart Fail 1 17 24 10.1161/CIRCHEARTFAILURE.107.740704 1:CAS:528:DC%2BD1cXosFGnsLY%3D 19808266
74. R Dechend E Shagdarsuren P Gratze, et al. 2007 Low-dose renin inhibitor and low-dose AT(1)-receptor blocker therapy ameliorate target-organ damage in rats harbouring human renin and angiotensinogen genes J Renin Angiotensin Aldosterone Syst 8 81 84 10.3317/jraas.2007.008 1:CAS:528:DC%2BD2sXhtVWgtLrF 17703434 (Pubitemid 47272471)
75. DJ Kelly Y Zhang G Moe G Naik RE Gilbert 2007 Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats Diabetologia 50 2398 2404 10.1007/s00125-007-0795-9 1:CAS:528: DC%2BD2sXhtFSlsL%2FI 17828524 (Pubitemid 47512400)
76. DL Feldman L Jin H Xuan, et al. 2008 Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats Hypertension 52 130 136 10.1161/HYPERTENSIONAHA.107.108845 1:CAS:528:DC%2BD1cXntVaisL0%3D 18490518
77. B Pilz E Shagdarsuren M Wellner, et al. 2005 Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats Hypertension 46 569 576 10.1161/01.HYP.0000179573.91016.3f 1:CAS:528: DC%2BD2MXptVWku7c%3D 16103264 (Pubitemid 41376839)
78. F Persson P Rossing KJ Schjoedt, et al. 2008 Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes Kidney Int 73 1419 1425 10.1038/ki.2008.68 1:CAS:528: DC%2BD1cXmsFehsr4%3D 18337712 (Pubitemid 351770494)
79. BH Oh J Mitchell JR Herron, et al. 2007 Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension J Am Coll Cardiol 49 1157 1163 10.1016/j.jacc.2006.11.032 1:CAS:528:DC%2BD2sXjtVagurk%3D 17367658 (Pubitemid 46400330)
80. K Andersen MH Weinberger B Egan, et al. 2008 Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial J Hypertens 26 589 599 10.1097/HJH.0b013e3282f3ad9a 1:CAS:528:DC%2BD1cXisVWhur0%3D 18300872 (Pubitemid 351317270)
81. A Stanton C Jensen J Nussberger E O'Brien 2003 Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren Hypertension 42 1137 1143 10.1161/01.HYP.0000101688.17370.87 1:CAS:528:DC%2BD3sXpsVGisrg%3D 14597641 (Pubitemid 37549068)
82. HH Parving F Persson JB Lewis EJ Lewis NK Hollenberg 2008 Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 2433 2446 10.1056/NEJMoa0708379 1:CAS:528:DC%2BD1cXmvFKmtLY%3D 18525041 (Pubitemid 351793017)
83. HH Parving BM Brenner JJ McMurray, et al. 2009 Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design Nephrol Dial Transplant 24 1663 1671 10.1093/ndt/gfn721 1:CAS:528: DC%2BD1MXkvFKjsLs%3D 19145003
84. MR Weir C Bush DR Anderson, et al. 2007 Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis J Am Soc Hypertens 1 264 277 10.1016/j.jash.2007.04.004 20409858 (Pubitemid 47091546)
85. SG Chrysant AV Murray UC Hoppe, et al. 2008 Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis Curr Med Res Opin 24 1039 1047 10.1185/030079908X280581 1:CAS:528:DC%2BD1cXmsVWgtbg%3D 18307835 (Pubitemid 351579161)
86. BF Palmer 2004 Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 585 592 10.1056/NEJMra035279 1:CAS:528:DC%2BD2cXmtF2ru7o%3D 15295051 (Pubitemid 39025174)